3l16: Difference between revisions

Revision as of 11:27, 17 February 2010

This article has been automatically seeded. Changes to this page should pertain to the PDB entry only and not to the protein or biomolecule in general.

File:3l16.jpg

Template:STRUCTURE 3l16

Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of CancerDiscovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer

Template:ABSTRACT PUBMED 20050669

About this StructureAbout this Structure

3L16 is a 1 chain structure with sequence from Homo sapiens. Full crystallographic information is available from OCA.

ReferenceReference

^{[xtra 1]}

↑ Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R, Heffron T, Lee L, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Prior WW, Salphati L, Sideris S, Tian Q, Tsui V, Wan NC, Wang S, Wiesmann C, Wong S, Zhu BY. Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer. J Med Chem. 2010 Feb 11;53(3):1086-97. PMID:20050669 doi:10.1021/jm901284w

Page seeded by OCA on Wed Feb 17 10:27:58 2010

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

[1] Sutherlin DP, Sampath D, Berry M, Castanedo G, Chang Z, Chuckowree I, Dotson J, Folkes A, Friedman L, Goldsmith R, Heffron T, Lee L, Lesnick J, Lewis C, Mathieu S, Nonomiya J, Olivero A, Pang J, Prior WW, Salphati L, Sideris S, Tian Q, Tsui V, Wan NC, Wang S, Wiesmann C, Wong S, Zhu BY. Discovery of (Thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer. J Med Chem. 2010 Feb 11;53(3):1086-97. PMID:20050669 doi:10.1021/jm901284w

[xtra 1]

@@ Line 1: / Line 1: @@
-'''Unreleased structure'''
+{{Seed}}
+[[Image:3l16.jpg|left|200px]]
-The entry 3l16 is ON HOLD
+<!--
+The line below this paragraph, containing "STRUCTURE_3l16", creates the "Structure Box" on the page.
+You may change the PDB parameter (which sets the PDB file loaded into the applet)
+or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
+or leave the SCENE parameter empty for the default display.
+-->
+{{STRUCTURE_3l16|  PDB=3l16  |  SCENE=  }}
-Authors: Murray, J.M., Wiesmann, C.
+===Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer===
-Description: Discovery of (thienopyrimidin-2-yl)aminopyrimidines as Potent, Selective, and Orally Available Pan-PI3-Kinase and Dual Pan-PI3-Kinase/mTOR Inhibitors for the Treatment of Cancer
-''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Dec 23 09:25:25 2009''
+<!--
+The line below this paragraph, {{ABSTRACT_PUBMED_20050669}}, adds the Publication Abstract to the page
+(as it appears on PubMed at http://www.pubmed.gov), where 20050669 is the PubMed ID number.
+-->
+{{ABSTRACT_PUBMED_20050669}}
+==About this Structure==
+L16 is a 1 chain structure with sequence from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3L16 OCA].
+==Reference==
+<ref group="xtra">PMID:20050669</ref><references group="xtra"/>
+[[Category: Homo sapiens]]
+[[Category: Phosphatidylinositol-4,5-bisphosphate 3-kinase]]
+[[Category: Murray, J M.]]
+[[Category: Wiesmann, C.]]
+[[Category: Atp-binding]]
+[[Category: Kinase]]
+[[Category: Nucleotide-binding]]
+[[Category: Pi3k-gamma p110 gamma]]
+[[Category: Transferase]]
+''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Wed Feb 17 10:27:58 2010''